
Insmed, Moderna, AbbVie, Amgen, SELLAS Life Sciences Group, Natera, and Danaher are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that use biological science to develop products or services, such as medicines, vaccines, and diagnostic tests. For investors, they can offer growth potential but often carry higher risk because a company’s prospects may depend on clinical-trial results, regulatory approval, and funding. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Insmed (INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
INSM traded up $22.06 during midday trading on Thursday, reaching $141.86. The company had a trading volume of 8,751,343 shares, compared to its average volume of 3,016,869. The business has a 50-day moving average of $110.51 and a two-hundred day moving average of $122.84. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77. Insmed has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a market cap of $31.12 billion, a P/E ratio of -50.53 and a beta of 0.83.
Read Our Latest Research Report on INSM
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Shares of NASDAQ MRNA traded up $2.54 during mid-day trading on Thursday, reaching $199.33. The company’s stock had a trading volume of 3,666,916 shares, compared to its average volume of 12,462,597. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.62 and a quick ratio of 3.47. Moderna has a 52 week low of $22.28 and a 52 week high of $280.80. The stock has a fifty day moving average of $205.61 and a two-hundred day moving average of $98.82. The firm has a market capitalization of $80.65 billion, a PE ratio of -27.96 and a beta of 1.16.
Read Our Latest Research Report on MRNA
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV stock traded down $3.55 during mid-day trading on Thursday, hitting $282.46. The company had a trading volume of 1,628,699 shares, compared to its average volume of 6,256,167. The stock’s 50 day moving average price is $277.84 and its 200-day moving average price is $241.96. AbbVie has a 52-week low of $190.75 and a 52-week high of $302.93. The company has a market capitalization of $499.28 billion, a P/E ratio of 48.59, a P/E/G ratio of 1.33 and a beta of 0.20.
Read Our Latest Research Report on ABBV
Amgen (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Shares of Amgen stock traded down $2.07 during trading on Thursday, reaching $441.82. 821,513 shares of the stock traded hands, compared to its average volume of 2,736,275. Amgen has a 52-week low of $312.39 and a 52-week high of $483.99. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. The business has a fifty day simple moving average of $428.15 and a two-hundred day simple moving average of $382.85. The company has a market capitalization of $238.98 billion, a price-to-earnings ratio of 25.59, a P/E/G ratio of 3.19 and a beta of 0.43.
Read Our Latest Research Report on AMGN
SELLAS Life Sciences Group (SLS)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Shares of NASDAQ SLS traded down $3.29 during midday trading on Thursday, reaching $14.66. 23,061,720 shares of the stock traded hands, compared to its average volume of 8,558,201. The stock has a market capitalization of $2.99 billion, a PE ratio of -72.52 and a beta of 2.73. SELLAS Life Sciences Group has a one year low of $1.39 and a one year high of $24.89. The company’s 50 day moving average is $11.09 and its 200 day moving average is $8.94.
Read Our Latest Research Report on SLS
Natera (NTRA)
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Natera stock traded up $7.08 during trading hours on Thursday, reaching $296.58. The stock had a trading volume of 942,119 shares, compared to its average volume of 1,474,901. The company has a market cap of $43.01 billion, a price-to-earnings ratio of -261.17 and a beta of 1.55. The business’s 50 day moving average price is $377.35 and its 200-day moving average price is $272.44. Natera has a 52 week low of $181.00 and a 52 week high of $437.41.
Read Our Latest Research Report on NTRA
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of Danaher stock traded down $0.76 on Thursday, reaching $227.82. The stock had a trading volume of 1,061,529 shares, compared to its average volume of 4,395,900. The company has a 50 day moving average price of $223.88 and a 200 day moving average price of $201.62. The company has a quick ratio of 1.29, a current ratio of 1.63 and a debt-to-equity ratio of 0.45. Danaher has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market capitalization of $160.28 billion, a P/E ratio of 37.37, a P/E/G ratio of 2.84 and a beta of 0.76.
Read Our Latest Research Report on DHR
Further Reading
- MarketBeat’s Top Five Stocks to Own in November 2026
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
- 3 Niche ETFs Are Beating the S&P 500, and Their Strategies Are Anything but Typical
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
